These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

860 related items for PubMed ID: 27863429

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M.
    Clin Cancer Res; 2007 Feb 15; 13(4):1341-9. PubMed ID: 17317846
    [Abstract] [Full Text] [Related]

  • 3. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
    Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H.
    Endocrine; 2012 Oct 15; 42(2):404-10. PubMed ID: 22426956
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
    Cao YM, Gu J, Zhang YS, Wei WJ, Qu N, Wen D, Liao T, Shi RL, Zhang L, Ji QH, Wang Y, Sun GH, Zhao YX, Wang YJ, Yu J, Zhu YX.
    Oncol Rep; 2018 Jan 15; 39(1):338-348. PubMed ID: 29115628
    [Abstract] [Full Text] [Related]

  • 6. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
    Wakasa T, Li Y, Bai Y, Liu Z, Ozaki T, Mori I, Miyauchi A, Kakudo K, Nakamura M.
    Pathol Res Pract; 2014 Nov 15; 210(11):733-8. PubMed ID: 25085839
    [Abstract] [Full Text] [Related]

  • 7. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells.
    Hou P, Liu D, Xing M.
    Endocr Relat Cancer; 2011 Dec 15; 18(6):687-97. PubMed ID: 21937738
    [Abstract] [Full Text] [Related]

  • 8. Hypermethylation of the RSK4 promoter associated with BRAF V600E promotes papillary thyroid carcinoma.
    Yin Y, Che K, Hu J, Hua H, Dong A, Wang J, Yu J, Zhang Q, Zhao S, Zhao Y, Wang P, Wang F, Wang Y, Chi J, Sun W.
    Int J Oncol; 2020 May 15; 56(5):1284-1293. PubMed ID: 32319586
    [Abstract] [Full Text] [Related]

  • 9. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAFV600E mutation in papillary thyroid cancer cells.
    Yan R, Yang T, Zhai H, Zhou Z, Gao L, Li Y.
    J Cell Biochem; 2018 Nov 15; 119(11):8763-8772. PubMed ID: 30126001
    [Abstract] [Full Text] [Related]

  • 10. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
    Liao T, Qu N, Shi RL, Guo K, Ma B, Cao YM, Xiang J, Lu ZW, Zhu YX, Li DS, Ji QH.
    Oncotarget; 2017 Jan 03; 8(1):238-247. PubMed ID: 27462868
    [Abstract] [Full Text] [Related]

  • 11. Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAFV600E Mutation.
    Poyrazoğlu Ş, Bundak R, Baş F, Yeğen G, Şanlı Y, Darendeliler F.
    J Clin Res Pediatr Endocrinol; 2017 Sep 01; 9(3):185-193. PubMed ID: 28077340
    [Abstract] [Full Text] [Related]

  • 12. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, Song C, Castellanos-Rizaldos E, Makrigiorgos GM, Kurebayashi J, Nose V, Van Hummelen P, Bronson RT, Vinco M, Giordano TJ, Dias-Santagata D, Pandolfi PP, Nucera C.
    Oncotarget; 2015 Dec 15; 6(40):42445-67. PubMed ID: 26636651
    [Abstract] [Full Text] [Related]

  • 13. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
    Jin L, Chen E, Dong S, Cai Y, Zhang X, Zhou Y, Zeng R, Yang F, Pan C, Liu Y, Wu W, Xing M, Zhang X, Wang O.
    Oncotarget; 2016 Apr 05; 7(14):18346-55. PubMed ID: 26943032
    [Abstract] [Full Text] [Related]

  • 14. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
    Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C.
    Cancer; 2007 Sep 15; 110(6):1218-26. PubMed ID: 17685465
    [Abstract] [Full Text] [Related]

  • 15. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAFV600E mutation.
    Lee YK, Park KH, Park SH, Kim KJ, Shin DY, Nam KH, Chung WY, Lee EJ.
    Head Neck; 2018 Oct 15; 40(10):2271-2279. PubMed ID: 29935011
    [Abstract] [Full Text] [Related]

  • 16. Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advanced stages in papillary thyroid carcinoma.
    Zou M, BinHumaid FS, Alzahrani AS, Baitei EY, Al-Mohanna FA, Meyer BF, Shi Y.
    Clin Endocrinol (Oxf); 2014 Jul 15; 81(1):109-16. PubMed ID: 24382015
    [Abstract] [Full Text] [Related]

  • 17. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.
    Guan H, Ji M, Hou P, Liu Z, Wang C, Shan Z, Teng W, Xing M.
    Cancer; 2008 Jul 15; 113(2):247-55. PubMed ID: 18470905
    [Abstract] [Full Text] [Related]

  • 18. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
    Zou M, Baitei EY, Al-Rijjal RA, Parhar RS, Al-Mohanna FA, Kimura S, Pritchard C, Binessa HA, Alzahrani AS, Al-Khalaf HH, Hawwari A, Akhtar M, Assiri AM, Meyer BF, Shi Y.
    Oncogene; 2016 Apr 14; 35(15):1909-18. PubMed ID: 26477313
    [Abstract] [Full Text] [Related]

  • 19. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
    Chernaya G, Mikhno N, Khabalova T, Svyatchenko S, Mostovich L, Shevchenko S, Gulyaeva L.
    Surg Oncol; 2018 Dec 14; 27(4):702-708. PubMed ID: 30449496
    [Abstract] [Full Text] [Related]

  • 20. The synergic effect of BRAFV600E mutation and multifocality on central lymph node metastasis in unilateral papillary thyroid carcinoma.
    Qu HJ, Qu XY, Hu Z, Lin Y, Wang JR, Zheng CF, Tan Z.
    Endocr J; 2018 Jan 30; 65(1):113-120. PubMed ID: 29070763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.